---
created: '2026-02-13T17:51:32.208034Z'
description: Positron emission tomography using fluorodeoxyglucose to measure cerebral
  glucose metabolism. Reveals patterns of hypometabolism characteristic of different
  neurodegenerative diseases.
dg-home: false
dg-publish: true
gardenUsername: dev_admin
permalink: /garden/dev_admin/examination/fdg-pet/
slug: fdg-pet
tags:
- examination
- neuroimaging
- pet
- metabolism
- neurodegeneration
templateEngineOverride: njk
title: FDG-PET
type: examination
updated: '2026-02-13T17:51:32.208034Z'
---

{% raw %}
<h1>FDG-PET (Fluorodeoxyglucose PET)</h1>
<h2>Overview</h2>
<p>FDG-PET measures regional cerebral glucose metabolism, which reflects synaptic activity and neuronal function. In neurodegenerative diseases, characteristic patterns of hypometabolism precede structural atrophy and help differentiate between dementia subtypes. FDG-PET represents the &quot;N&quot; (neurodegeneration) component in the ATN biomarker framework.</p>
<h2>Mechanism</h2>
<h3>Tracer Behavior</h3>
<ul>
<li>18F-FDG is a glucose analog</li>
<li>Taken up by metabolically active cells</li>
<li>Phosphorylated by hexokinase → trapped in cells</li>
<li>Signal reflects regional glucose utilization</li>
<li>Half-life: 110 minutes</li>
</ul>
<h3>Brain Metabolism</h3>
<ul>
<li>Brain uses ~20% of body's glucose</li>
<li>Glucose metabolism correlates with synaptic activity</li>
<li>Hypometabolism indicates dysfunction or neurodegeneration</li>
</ul>
<h2>Disease-Specific Patterns</h2>
<h3>Alzheimer's Disease</h3>
<ul>
<li><strong>Classic pattern</strong>: Posterior cingulate, precuneus, temporoparietal</li>
<li><strong>Progression</strong>: Bilateral, spreading to frontal</li>
<li><strong>Spared</strong>: Sensorimotor cortex, visual cortex, basal ganglia</li>
<li><strong>&quot;AD signature&quot;</strong>: Highly characteristic</li>
</ul>
<h3>Frontotemporal Dementia</h3>
<ul>
<li><strong>bvFTD</strong>: Frontal and anterior temporal hypometabolism</li>
<li><strong>svPPA</strong>: Left anterior temporal predominant</li>
<li><strong>nfvPPA</strong>: Left frontal operculum, insula</li>
<li>Asymmetry common</li>
</ul>
<h3>Dementia with Lewy Bodies</h3>
<ul>
<li><strong>Occipital hypometabolism</strong>: Distinguishes from AD</li>
<li>&quot;Cingulate island sign&quot;: Preserved posterior cingulate</li>
<li>Visual cortex involvement (visual hallucinations)</li>
</ul>
<h3>Parkinson's Disease Dementia</h3>
<ul>
<li>Similar to DLB</li>
<li>Occipital involvement</li>
<li>May overlap with AD pattern in mixed cases</li>
</ul>
<h3>Vascular Dementia</h3>
<ul>
<li>Multifocal, patchy hypometabolism</li>
<li>Corresponds to infarct locations</li>
<li>Less characteristic pattern</li>
</ul>
<h3>Corticobasal Syndrome</h3>
<ul>
<li>Asymmetric frontoparietal hypometabolism</li>
<li>Contralateral to symptomatic side</li>
<li>Basal ganglia may show changes</li>
</ul>
<h3>Progressive Supranuclear Palsy</h3>
<ul>
<li>Frontal, especially medial frontal</li>
<li>Midbrain hypometabolism</li>
<li>&quot;Striatal pattern&quot; in some cases</li>
</ul>
<h2>Quantitative Analysis</h2>
<h3>Visual Assessment</h3>
<ul>
<li>Side-by-side comparison with normal database</li>
<li>Pattern recognition by trained readers</li>
<li>Sensitivity ~90%, specificity ~85%</li>
</ul>
<h3>Statistical Parametric Mapping</h3>
<ul>
<li>Voxel-based comparison to normal controls</li>
<li>Z-score maps highlight abnormalities</li>
<li>NeuroQ, Cortex ID, Syngo.via</li>
</ul>
<h3>SUVR Quantification</h3>
<ul>
<li>Regional standardized uptake value ratios</li>
<li>Pons or whole brain reference</li>
<li>Longitudinal comparison</li>
</ul>
<h2>Clinical Applications</h2>
<h3>Dementia Differential Diagnosis</h3>
<ol>
<li>AD vs FTD (different patterns)</li>
<li>DLB vs AD (occipital involvement)</li>
<li>Atypical presentations</li>
<li>Young-onset dementia</li>
</ol>
<h3>Prognosis</h3>
<ul>
<li>Severity of hypometabolism predicts decline</li>
<li>Rate of metabolic change tracks progression</li>
<li>Worse metabolism = faster decline</li>
</ul>
<h3>Treatment Monitoring</h3>
<ul>
<li>Research: Tracking drug effects</li>
<li>May detect improvement or stabilization</li>
</ul>
<h2>ATN Framework Role</h2>
<h3>&quot;N&quot; Component</h3>
<ul>
<li>Neurodegeneration marker</li>
<li>Alternatives: MRI volumetry, CSF t-tau</li>
<li>Functional change may precede structural</li>
</ul>
<h3>Combined Interpretation</h3>
<ul>
<li>A+T+N+: Full AD pathology</li>
<li>A-T-N+: Suspected non-AD pathology (SNAP)</li>
<li>Metabolic patterns refine diagnosis</li>
</ul>
<h2>Relationships</h2>
<h3>Conditions</h3>
<ul>
<li>→ <a href="/garden/dev_admin/condition/alzheimers-disease/" class="internal-link">Alzheimer's Disease</a> (condition) - <em>Temporoparietal pattern</em></li>
<li>→ <a href="/garden/dev_admin/condition/frontotemporal-dementia/" class="internal-link">Frontotemporal Dementia</a> (condition) - <em>Frontal pattern</em></li>
<li>→ <a href="/garden/dev_admin/condition/lewy-body-dementia/" class="internal-link">Lewy Body Dementia</a> (condition) - <em>Occipital involvement</em></li>
<li>→ <a href="/garden/dev_admin/condition/vascular-dementia/" class="internal-link">Vascular Dementia</a> (condition) - <em>Patchy, multifocal</em></li>
<li>→ <a href="/garden/dev_admin/condition/mild-cognitive-impairment/" class="internal-link">Mild Cognitive Impairment</a> (condition) - <em>Predicts conversion</em></li>
</ul>
<h3>Related Imaging</h3>
<ul>
<li>→ <a href="/garden/dev_admin/examination/amyloid-pet-imaging/" class="internal-link">Amyloid PET Imaging</a> (examination) - <em>ATN A component</em></li>
<li>→ <a href="/garden/dev_admin/examination/tau-pet-imaging/" class="internal-link">Tau PET Imaging</a> (examination) - <em>ATN T component</em></li>
<li>→ <a href="/garden/dev_admin/examination/mri-volumetry/" class="internal-link">MRI Volumetry</a> (examination) - <em>Structural correlate</em></li>
</ul>
<h3>Brain Regions</h3>
<ul>
<li>→ <a href="/garden/dev_admin/organ/posterior-cingulate-cortex/" class="internal-link">Posterior Cingulate Cortex</a> (organ) - <em>Early AD involvement</em></li>
<li>→ <a href="/garden/dev_admin/organ/precuneus/" class="internal-link">Precuneus</a> (organ) - <em>AD signature region</em></li>
<li>→ <a href="/garden/dev_admin/organ/prefrontal-cortex/" class="internal-link">Prefrontal Cortex</a> (organ) - <em>FTD involvement</em></li>
</ul>
<h2>Advantages and Limitations</h2>
<h3>Advantages</h3>
<ul>
<li>Well-established technique</li>
<li>Widely available (oncology infrastructure)</li>
<li>Excellent differential diagnosis</li>
<li>Medicare coverage for dementia</li>
</ul>
<h3>Limitations</h3>
<ul>
<li>Radiation exposure (~7 mSv)</li>
<li>Cost (~$2,500-4,000)</li>
<li>Non-specific (reflects any cause of hypometabolism)</li>
<li>Affected by blood glucose levels</li>
<li>Requires fasting and quiet environment</li>
</ul>
<h2>Practical Considerations</h2>
<h3>Patient Preparation</h3>
<ul>
<li>4-6 hour fast (water allowed)</li>
<li>Blood glucose &lt;200 mg/dL (ideally &lt;150)</li>
<li>Quiet, dimly lit environment during uptake</li>
<li>Avoid stimulation during 30-45 min uptake period</li>
</ul>
<h3>Image Acquisition</h3>
<ul>
<li>Scan starts ~30-45 min post-injection</li>
<li>10-20 minute acquisition</li>
<li>CT for attenuation correction</li>
</ul>
<h2>References</h2>
<ol>
<li><strong>AD Pattern</strong>: Minoshima, S., et al. (1997). &quot;Metabolic reduction in posterior cingulate cortex in early AD.&quot; <em>Annals of Neurology</em>.</li>
<li><strong>Differential Diagnosis</strong>: Defined, E., et al. (2019). &quot;FDG-PET in dementia.&quot; <em>Seminars in Nuclear Medicine</em>.</li>
<li><strong>ATN Framework</strong>: Jack, C.R., et al. (2018). &quot;NIA-AA Research Framework.&quot; <em>Alzheimer's &amp; Dementia</em>.</li>
</ol>

{% endraw %}